Ignite Creation Date:
2025-12-24 @ 7:12 PM
Ignite Modification Date:
2025-12-25 @ 4:48 PM
Study NCT ID:
NCT06015503
Status:
RECRUITING
Last Update Posted:
2025-04-03
First Post:
2023-08-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Sponsor:
Avistone Biotechnology Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-21
Start Date Type:
ACTUAL
Primary Completion Date:
2025-03-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-10-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-18
First Submit QC Date:
None
Study First Post Date:
2023-08-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-31
Last Update Post Date:
2025-04-03
Last Update Post Date Type:
ACTUAL